Svoz Drug Interactions

Clinically important pharmacokinetic interactions have not been reported when warfarin and Moxifloxacin were used concomitantly. However, concurrent use of fluoroquinolones including Moxifloxacin may enhance the anticoagulant effect of vitamin K antagonists (e.g. warfarin) which may result in increased risk of bleeding. The prothrombin time (PT), international normalized ratio (INR) and other suitable coagulation tests should be monitored in patients receiving Moxifloxacin concomitantly with warfarin.
Svoz: The use of Moxifloxacin concomitantly with sucralfate, didanosine, antacid containing magnesium, aluminium or calcium, vitamins and minerals containing metal cations such as iron and zinc will decrease the absorption of Moxifloxacin; calcium supplements have no clinically important pharmacokinetic interaction with Moxifloxacin.
Therefore, Moxifloxacin should be administered at least 4 hours before or 8 hours after these preparations.
The use of Moxifloxacin with other drugs that prolong the QT interval including amiodarone, astemizole, bepridil, cisapride, disopyramide, erythromycin, pentamidine, chlorpromazine, fluphenazine, methotrimeprazine, perphenazine, prochlorperazine, promazine, thioridazine, trifluoperazine, triflupromazine, procainamide, quinidine, sotalol, terfenadine, amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine may lead to arrhythmias (including torsades de pointes).
The use of Moxifloxacin with corticosteroids may increase the risk of severe tendon disorders such as tendonitis, tendon rupture.
Svoz Infusion: Concomitant use of Moxifloxacin and class IA (e.g. quinidine, procainamide) or class III (e.g. amiodarone, sotalol) antiarrhythmic agents should be avoided. Moxifloxacin should be used with caution in patients receiving other drugs that prolong the QT interval (e.g. cisapride, erythromycin, antipsychotic agents, tricyclic antidepressant) because concurrent use of Moxifloxacin and these drugs may result in increased risk of QT interval prolongation.
Concomitant use of Moxifloxacin with corticosteroids increase the risk of severe tendon disorders (e.g. tendonitis, tendon rupture), especially in geriatric patients older than 60 years of age. Patients receiving Moxifloxacin concomitantly with corticosteroids should be monitored.
No clinically important pharmacokinetic interactions between digoxin and Moxifloxacin. Although a transient increase in digoxin concentration may occur, this is not considered clinically important. Dosage adjustments are not necessary for either drug.